Lokesh Pg Dalasanur Nagaprashantha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/976817/publications.pdf Version: 2024-02-01



LOKESH PG DALASANUR

#	Article	IF	CITATIONS
1	Translational opportunities for broadâ€ s pectrum natural phytochemicals and targeted agent combinations in breast cancer. International Journal of Cancer, 2018, 142, 658-670.	5.1	21
2	Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment. Cancer Letters, 2018, 413, 122-134.	7.2	400
3	2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. Oncotarget, 2018, 9, 18053-18068.	1.8	21
4	Nutlinâ€3 enhances sorafenib efficacy in renal cell carcinoma. Molecular Carcinogenesis, 2013, 52, 39-48.	2.7	26
5	Proteomic Analysis of Signaling Network Regulation in Renal Cell Carcinomas with Differential Hypoxia-Inducible Factor-2α Expression. PLoS ONE, 2013, 8, e71654.	2.5	10
6	Didymin Induces Apoptosis by Inhibiting N-Myc and Upregulating RKIP in Neuroblastoma. Cancer Prevention Research, 2012, 5, 473-483.	1.5	41
7	RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer. PLoS ONE, 2012, 7, e34582.	2.5	38
8	Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors. Pharmaceutical Research, 2012, 29, 621-636.	3.5	18
9	RLIP76, a Clutathione-Conjugate Transporter, Plays a Major Role in the Pathogenesis of Metabolic Syndrome. PLoS ONE, 2011, 6, e24688.	2.5	44
10	Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochemical Pharmacology, 2011, 82, 1100-1109.	4.4	97
11	The sensors and regulators of cell–matrix surveillance in anoikis resistance of tumors. International Journal of Cancer, 2011, 128, 743-752.	5.1	68
12	Targeting p53-Null Neuroblastomas through RLIP76. Cancer Prevention Research, 2011, 4, 879-889.	1.5	20
13	2'-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma. Carcinogenesis, 2011, 32, 568-575.	2.8	34

Abstract 4334: Targeting p53 null neuroblastomas through RLIP76., 2011, , .

1